These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 24692701)

  • 1. Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model.
    Kim YI; Kim KW; Lee HK; Park J; Chung JW; Youn H; Kim SJ; Kim DH; Tseng JC; Lee JM
    Anticancer Res; 2014 Apr; 34(4):1715-22. PubMed ID: 24692701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
    Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
    Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516.
    Ham SJ; Choi Y; Lee SI; Kim J; Kim YI; Chung JW; Kim KW
    Hepatol Int; 2017 Sep; 11(5):446-451. PubMed ID: 28721452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study.
    Lee IJ; Lee M; Kim SJ; Kim YK; Won JY; Chung JW
    J Vasc Interv Radiol; 2018 Aug; 29(8):1078-1084. PubMed ID: 29910164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
    Hossain MA; Kim DH; Jang JY; Kang YJ; Yoon JH; Moon JO; Chung HY; Kim GY; Choi YH; Copple BL; Kim ND
    Int J Oncol; 2012 May; 40(5):1636-42. PubMed ID: 22322725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
    Kim MY; Shin JY; Kim JO; Son KH; Kim YS; Jung CK; Kang JH
    BMC Cancer; 2020 Nov; 20(1):1057. PubMed ID: 33143663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
    Kwak MS; Yu SJ; Yoon JH; Lee SH; Lee SM; Lee JH; Kim YJ; Lee HS; Kim CY
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2037-45. PubMed ID: 25989942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
    Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
    Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells.
    Pan YY; Xu SP; Jia XY; Xu HQ; Zhang Y; Rui LX; Wei W
    Exp Oncol; 2007 Mar; 29(1):23-9. PubMed ID: 17431384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H; Ong R; Soo KC
    Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion.
    Xie Z; Choong PF; Poon LF; Zhou J; Khng J; Jasinghe VJ; Palaniyandi S; Chen CS
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):949-57. PubMed ID: 18259754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
    Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
    Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice.
    Nonaka K; Onizuka S; Ishibashi H; Uto Y; Hori H; Nakayama T; Matsuura N; Kanematsu T; Fujioka H
    J Surg Res; 2012 Jan; 172(1):116-22. PubMed ID: 20855083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.